Navigation Links
K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants
Date:8/3/2010

adverse effect, if any, on its revenue, assets and liquidity and capital resources, as more fully described in Note 20 – "Subsequent Events" of the Notes to the Consolidated Financial Statements in the Form 10-Q;
  • changes in the current and future business environment, including interest rates and capital and consumer spending;
  • the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized;
  • the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals, including with respect to Gestiva™, as well as the number of preterm births for which Gestiva™ may be prescribed, its safety profile and side effects profile;
  • acceptance of and demand for the Company's new pharmaceutical products or current products upon their return to the marketplace;
  • the introduction and impact of competitive products and pricing, including as a result of so-called authorized generic drugs;
  • new product development and launch, including the possibility that any product launch may be delayed;
  • reliance on key strategic acquisitions;
  • the availability of raw materials and/or products manufactured for the Company under contract manufacturing agreements with third parties;
  • the regulatory environment, including regulatory agency and judicial actions and changes in applicable laws or regulations;
  • fluctuations in revenues;
  • the difficulty of predicting international regulatory approvals, including timing;
  • the difficulty of predicting the pattern of inventory movements by the Company's customers;
  • the impact of competitive response to the Company's sales, marketing and strategic efforts, including introduction or potential introduction of generic or competing products against products sold by the Company and its subsidiaries;
  • risks that the Company may not ultimately prevail in litigation, including product li
    '/>"/>

  • SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
    2. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
    3. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
    4. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
    5. China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
    6. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
    7. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
    8. Viscira Delivers Key Presentation to Pharmaceutical Marketing Professionals at Leading Digital Industry Conference
    9. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
    10. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
    11. Angiotech Pharmaceuticals Announces Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
    (Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
    (Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
    (Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
    Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
    ... 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... its corporate partner, Boston Scientific Corporation (NYSE: ... U.S. Food and Drug Administration (FDA) to market ... a highly deliverable, next-generation drug-eluting stent (DES) specifically ...
    ... Data from Phase II Study Evaluating Bavituximab in ... Data from Phase I Study Evaluating Bavituximab in ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a ... the treatment of cancer and serious virus infections, ...
    ... Corporation (NYSE: BSX ) today announced it ... Administration (FDA) to market its TAXUS(R) Liberte (R) ... drug-eluting stent (DES) specifically designed for treating small coronary ... as small as 2.25 mm in diameter and joins ...
    Cached Biology Technology:Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 2Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 3Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 4Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 5Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 2Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 3Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 4FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 2FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 3FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 4
    (Date:4/16/2014)... densely packed array of finger-like projections called microvilli ... line our intestines., Vanderbilt University researchers have now ... which is critical for absorbing nutrients and defending ... the journal Cell , reveal a role ... increase our understanding of intestinal pathologies associated with ...
    (Date:4/16/2014)... Geologic and soil processes are to blame for significant ... to a study published recently in the Journal ... soil samples from all corners of Ohio showed that ... level of concern recommended by the U.S. Environmental Protection ... the authors, who note that regulatory levels typically are ...
    (Date:4/15/2014)... CA Photosynthesis provides fixed carbon and energy for nearly ... fascinating process remain mysterious. For example, little is known ... in light intensity. More fundamentally, we do not know ... machines that perform photosynthesis in any organism. , , ... reinhardtii is a leading subject for photosynthesis research. ...
    Breaking Biology News(10 mins):Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4
    ... of the worlds leading marine biologists will gather in Auckland ... life from the poles to the tropics. This major meeting ... Marine Life, is being jointly hosted by the National Institute ... Auckland. The Census of Marine Life is ...
    ... As housing developments sprout across the United States, smart ... concentrated pockets, instead of the more standard and familiar ... on the environment, affecting a smaller portion of the ... for cluster development was to protect open space, farmland, ...
    ... often focuses only on the numbers of vertebrate animals ... the tropics. But what about the other organisms, ... the species richness of flowering plants and mammals is ... taxonomists, ecologists, and philosophers explored the worlds southernmost forest ...
    Cached Biology News:Location, location, location 2Location, location, location 3The conservation lens 2The conservation lens 3
    Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
    Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
    ...
    Guanine nucleotide-binding protein G(k), alpha subunit...
    Biology Products: